By Tom Whitfield

Difamilast, a topical phosphodiesterase 4 (PDE4) inhibitor, won FDA approval for atopic dermatitis, Pharmacy Times reported. It becomes the second topical PDE4 inhibitor cleared for U.S. patients with the chronic inflammatory skin condition.

Crisaborole (Eucrisa), approved in December 2016, was the first. It carved out a niche as a non-steroidal option for mild-to-moderate atopic dermatitis, with later pediatric label extensions down to 3 months of age. Tolerability complaints — burning and stinging on application — throttled real-world uptake despite clinical efficacy.

Atopic dermatitis affects roughly 16.5 million U.S. adults and about 7.5 million children, per the National Eczema Association. Annual U.S. healthcare spending on the disease tops $5 billion, federal analyses show, fueling demand for new topical tools.

Why does a second PDE4 inhibitor matter?

Topical corticosteroids still anchor atopic dermatitis treatment. Steroid phobia — patient and parent reluctance to use them on the face, eyelids or intertriginous zones — has pushed dermatologists toward non-steroidal alternatives for decades. Topical calcineurin inhibitors (tacrolimus, pimecrolimus) filled that gap after 2000, then carried black-box cancer warnings. Steroid phobia drove the demand, and pharma responded: crisaborole in 2016, difamilast now.

The PDE4 mechanism blocks phosphodiesterase 4, an enzyme that drives cytokine production. Crisaborole's pivotal data showed roughly 32% of patients hitting clear or almost-clear skin at four weeks vs. 22% on vehicle — modest, but enough to clear the FDA bar in 2016.

What's in the source — and what isn't?

Pharmacy Times' headline doesn't include EASI or IGA endpoints, vehicle formulation, dosing strength, pediatric age range, or approval date. The linked article body wasn't retrievable at the time of this rewrite.

Dermatology practices tracking difamilast should pull the FDA approval letter and full prescribing information from Drugs@FDA for definitive trial endpoints, age range, and indication language. The full Pharmacy Times article is the next stop for pricing, launch timing, and the U.S. commercial partner.

Where does difamilast fit in the broader AD pipeline?

Difamilast arrives in a market reshaped by dupilumab (Dupixent), approved in 2017, and JAK inhibitors (upadacitinib, abrocitinib, ruxolitinib cream) cleared since 2021. Tapinarof cream (Vtama), an aryl hydrocarbon receptor agonist, won FDA approval for atopic dermatitis in 2024, adding another non-steroidal topical to the mix.

A second topical PDE4 inhibitor gives prescribers another option for steroid-averse patients or for facial and intertriginous sites where corticosteroid atrophy remains a real concern. Difamilast's place in this expanded toolbox hinges on efficacy data, tolerability profile, and pricing — none of which sit in the source headline.

How will the prescribing picture change?

Prescribers who reach for crisaborole typically do so on the face, eyelids, and intertriginous zones. Steroid atrophy on these sites pushes clinicians off corticosteroids and onto non-steroidal topicals, even when efficacy is modest. Difamilast, if it matches crisaborole's IGA profile while improving tolerability, could claim that same clinical use case — or expand it to patients who refused crisaborole after stinging reactions.

Pediatric atopic dermatitis offers the largest patient pool for any topical, with roughly 7.5 million U.S. kids on the National Eczema Association's running tally. Whether difamilast lands an FDA pediatric label, and at what age, will drive pediatric prescribing more than any other factor.

What's next for difamilast?

Payer coverage decisions will shape access; dermatologists should watch Medicare and commercial formulary placements. Coding and reimbursement specifics will determine how fast the drug reaches a typical prescription pad. Any head-to-head data against crisaborole will tell prescribers where difamilast actually fits. Until then, U.S. dermatologists have a new option in the topical PDE4 class — and several unanswered questions about it. Watch the FDA approval letter for the boxed-warning status, age range, and any pediatric exclusivity.